Bone safety with risedronate: histomorphometric studies at different dose levels and exposure

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

(2012) Michael R. McClung et al.   CALCIFIED TISSUE INTERNATIONAL

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

(2012) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Issues in modern bone histomorphometry

(2011) R.R. Recker et al.   BONE

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

(2011) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females

(2010) Robert R. Recker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

(2010) A. Michael Parfitt et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment of osteoporosis with denosumab

(2010) E. Michael Lewiecki   MATURITAS

Comparison between 150 mg monthly and 5 mg daily risedronate in postmenopausal osteoporosis; Effects on bone quality and bone remodelling

(2009) P. Chavassieux et al.   BONE

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA study

(2009) Robert R. Recker et al.   BONE

Risedronate reduces intracortical porosity in women with osteoporosis

(2009) Babul Borah et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Alendronate on Bone Quality and Remodeling in Glucocorticoid-Induced Osteoporosis: A Histomorphometric Analysis of Transiliac Biopsies

(2006) Pascale M. Chavassieux et al.   JOURNAL OF BONE AND MINERAL RESEARCH